How The Coronavirus Could Bolster Innovation Arguments Against US Price Controls
The Trump administration does not believe its partnership with industry on therapeutics for COVID-19 should include conditions on pricing, US Health Secretary Alex Azar tells Congress.
You may also be interested in...
Studies show net prices increases, R&D spending lower than often cited, and better profit margins other industries. But pharma pushes back with concerns about study designs and maintains the picture has changed in more recent years.
The US government has a routine approach for negotiating single-seller/single-buyer contracts, but drug pricing politics and public fears of coronavirus will likely complicate any purchasing talks with a sponsor, should an effective vaccine or therapeutic emerge.
When the top US health official testified before Congress on the budget this past week, drug pricing was barely discussed. What a difference two weeks – and global spread of a novel infectious disease – makes.